INmune Bio, Inc. (NASDAQ:INMB) Short Interest Up 5.6% in October

INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) was the target of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 2,830,000 shares, a growth of 5.6% from the September 30th total of 2,680,000 shares. Based on an average trading volume of 225,300 shares, the days-to-cover ratio is presently 12.6 days.

Insider Buying and Selling

In related news, CFO David J. Moss purchased 7,690 shares of INmune Bio stock in a transaction that occurred on Thursday, September 12th. The stock was bought at an average price of $6.38 per share, for a total transaction of $49,062.20. Following the completion of the transaction, the chief financial officer now owns 1,275,869 shares in the company, valued at $8,140,044.22. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Raymond Joseph Tesi acquired 15,380 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average cost of $6.38 per share, for a total transaction of $98,124.40. Following the purchase, the chief executive officer now owns 1,554,106 shares of the company's stock, valued at approximately $9,915,196.28. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO David J. Moss acquired 7,690 shares of the company's stock in a transaction on Thursday, September 12th. The shares were acquired at an average cost of $6.38 per share, for a total transaction of $49,062.20. Following the completion of the acquisition, the chief financial officer now owns 1,275,869 shares of the company's stock, valued at approximately $8,140,044.22. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 33,070 shares of company stock worth $200,087. 35.20% of the stock is owned by company insiders.

Institutional Trading of INmune Bio

A number of large investors have recently modified their holdings of INMB. Fermata Advisors LLC raised its stake in INmune Bio by 8.5% in the second quarter. Fermata Advisors LLC now owns 34,140 shares of the company's stock valued at $301,000 after purchasing an additional 2,689 shares in the last quarter. Westside Investment Management Inc. raised its position in shares of INmune Bio by 31.8% during the 2nd quarter. Westside Investment Management Inc. now owns 45,340 shares of the company's stock valued at $400,000 after buying an additional 10,950 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of INmune Bio by 124.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company's stock worth $517,000 after acquiring an additional 32,511 shares during the last quarter. Rhumbline Advisers purchased a new position in INmune Bio in the second quarter worth $121,000. Finally, Marshall Wace LLP increased its stake in INmune Bio by 332.1% in the second quarter. Marshall Wace LLP now owns 115,916 shares of the company's stock valued at $1,022,000 after acquiring an additional 89,091 shares during the last quarter. Institutional investors own 12.72% of the company's stock.

INmune Bio Stock Performance

NASDAQ INMB traded down $0.10 on Thursday, hitting $5.85. The stock had a trading volume of 168,812 shares, compared to its average volume of 163,310. The firm has a 50-day moving average of $5.67 and a 200-day moving average of $7.83. INmune Bio has a 52-week low of $4.78 and a 52-week high of $14.74. The company has a market capitalization of $115.60 million, a price-to-earnings ratio of -2.84 and a beta of 1.85.

INmune Bio (NASDAQ:INMB - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%. As a group, research analysts anticipate that INmune Bio will post -2.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

INMB has been the subject of several analyst reports. Alliance Global Partners assumed coverage on shares of INmune Bio in a report on Monday, October 21st. They issued a "buy" rating and a $20.00 price objective for the company. Scotiabank initiated coverage on INmune Bio in a research report on Thursday, August 22nd. They issued a "sector outperform" rating and a $22.00 price target for the company. Finally, Raymond James initiated coverage on INmune Bio in a report on Friday, September 27th. They set an "outperform" rating and a $18.00 price objective on the stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.